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Objective: Renal ischemia reperfusion (IR) injury (IRI) is an important mechanism of acute renal failure (ARF) and a
crucial factor of tissue damage during vascular surgery. IR may lead to tissue destruction and influence the early and
long-term outcome of organs. The anti-anginal medication trimetazidine (TMZ) is a drug, the protective effects of which
have been already assessed during cold preservation and warm ischemia (WI). The objective of this dose-effect study was
to assess the role of TMZ in severe renal WI model.
Materials andMethods:We have used an establishedWI pig kidney model associated with a uninephrectomy condition and
studied the dose-dependent role of TMZ (1, 5, and 10 mg/Kg, i.v. for 24 hours before WI) against deleterious effects of
WI (60 minutes of WI followed by reperfusion) compared with sham-operated (control) and uninephrectomized animals
(unif). Direct effect of TMZ was determined using different variables: renal function (creatinine clearance; Ccr) and
indirectly, the consequences on inflammation (cells infiltration), rate of apoptosis, fibrosis development, and renal
epithelial cells change into myofibroblast, which defined epithelial to mesenchymal transition (-smooth muscle actin
[-SMA] and vimentin expression).
Results: TMZ (5 or 10 mg/Kg) significantly increased Ccr and reduced the inflammatory response prevalent in ischemic
kidney injury and rate of apoptosis expression. In addition, the limitation of initial IRI was correlated with an earlier and
greater expression of hypoxia-inducible transcription factor-1 (HIF-1), which is a hypoxia marker during kidney
regeneration. A reduction of the tubulointerstitial development of fibrosis and a limitation of the -smooth muscle actin
expression (-SMA) was observed with TMZ treatment. At 3 months, vimentin expression was increased in WI groups
without TMZ or low TMZ dose treatment compared with 5 or 10 mg/Kg treated groups.
Conclusion: Collectively, these data suggest that TMZ made the warm ischemic kidneys more resistant to the deleterious
impact of a single episode of IR and could have a role in preserving the ischemic kidney from long-term damage. (J Vasc
Surg 2008;47:852-60.)
Clinical Relevance: Our results suggest that TMZ limits in a dose-dependent manner IRI after 60 minutes of WI. This
drug could be useful to prevent deleterious consequences of renal ischemia accompanied by a nephronic mass reduction
(which mimic clinical situation of patients with chronic nephropathy who are at risk for vascular diseases), during
thoracoabdominal aortic surgery, or operations with a planned period of WI (renal artery by-pass, juxta or supra-renal
and thoracoabdominal aneurysm repair and promote renal recovery in a preclinical model.From the Inserm, ERM324, Université de Poitiers, Poitiers,a the Labora-
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852Acute renal failure (ARF) is a syndrome characterized by an
acute loss of renal function and is an important clinical
problem.1 Acute tubular necrosis (ATN) with prerenal
disease is the most common cause of ARF, accounting for
two-thirds of intrinsic causes.2 Despite many advances in
vascular surgery, the incidence and attendant mortality of
postoperative ischemia reperfusion injury (IRI) is especially
high for patients having surgery for ruptured aneurysms
and, to those requiring temporary total renal ischemia, for
example, resection of thoracoabdominal (TAA) or suprare-
nal aortic cross clamping for aneurysms, extensive occlusive
disease and renal revascularization procedures.3-5
There is no established therapy that could accelerate
renal function recovery, and attempts at preventing ARF
are not always effective.6 There is increasing evidence that
ischemia reperfusion (IR) of an organ induces cellular
apoptosis through a complicated series of changes in mito-
chondria functions and structure.7,8 Consequently, mito-
chondria could be a pivotal target in this process, and
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therapeutic tools.7
We have previously observed the protective effect of
trimetazidine (TMZ) of kidney grafts from cold preserva-
tion and reperfusion, and shown that TMZ was effective
when added to different currently used preservation solu-
tions.9,10 Despite the care taken to preserve vital functions
in candidates for organ donation, explanted organs may
pass through a variable period of hypoxia and/or ischemia
secondary to a low renal blood flow with a consequent
deleterious effect on renal cell metabolism that may affect
function after transplantation. Because WI is a crucial factor
in the causation of tissue damage during a large number of
surgical procedures with a planned period of WI, particu-
larly for patients with reduced functional nephronic mass
(such as patients with chronic renal disease who are at risk
for vascular complications), we have designed this study to
assess TMZ effect. TMZ has different pharmacological
properties that could be relevant for the prevention of
organ damage from IRI.11-14 Other studies have suggested
a protective effect of TMZ by reduction of intracellular
acidosis, preservation of ATP production, limitation of in-
flammatory reaction, and thus of reactive oxygen species
(ROS) generation and prevention of calcium overload.15
Consistent with IRI pathophysiology, a recent study has sug-
gested a direct potential mechanism for TMZ by inhibiting
mitochondrial permeability transition pore opening (mPTP),
which participate in the early steps of cell death.16,17 Interest-
ingly, TMZ was shown to be involved in the process of tubular
repair via an earlier and greater expression of stathmin after
experimental WI of different durations.18 Stathmin is a mem-
ber of a group of proteins that bind to and destabilize the
microtubule networks and is important in the regulation of
cell proliferation and tissue regeneration after injury.19 There-
fore, to clarify the role of TMZ against lethal IRI, the present
study was designed: (1) to seek for an effect of TMZ on the
rate of apoptosis process in a dose effect manner and (2) to
study early and long-term effects of different TMZ doses
against WI injury followed by reperfusion.
METHODS
Surgical procedures and experimental groups.
Large white male pigs (31 to 38 Kg; INRA, Y Billon, Le
Magneraud, Surgères, France) were prepared as previously
described.9,10 A catheter was inserted in the jugular vein for
blood samples collection. WI was induced in the pigs by
clamping the left renal pedicle for 60 minutes (WI-60, n
6) with a vascular nontraumatic clamp followed by a right
nephrectomy to mimic nephronic mass reduction. TMZ
was administered i.v. (total dose 1, 5, and 10 mg/kg)
constant infusion over 24 hours before WI (WI-60-TMZ1
mg, n  6, WI-60-TMZ5 mg, n  6, and WI-60-TMZ10
mg, n  6) via jugular vein. These experimental groups
were compared with the uninephrectomized group (unif;
n 6, nephron mass, weight, and age-matched group) and
the control group (sham-operated: control; n 6, age and
weight matched group, dissection of the renal pedicle
without clamping procedure and mobilization of the con-trolateral kidney without nephrectomy). All experimental
groups were submitted to the same anesthesia protocol.
Animals were followed up for 12 weeks after WI. Addi-
tional animals were submitted to the same experimental
conditions and sacrificed at days 1 (n  3) and 7 (n  3)
after reperfusion for Western blot and proteins studies in
renal tissue. All experiments were carried out in accordance
with the Guidelines of the French Agricultural Office and
the legislation governing animal studies.
Functional parameters. Endogenous creatinine clear-
ance (Ccr, expressed in ml/min) and urinary proteins were
measured at days 1, 3, 5, 7, 11, and 14, and at months 1 and
3 after reperfusion as previously described.9 As previously
described, urine and plasma samples from animals in
control, unif, and ischemic kidneys groups were collected
and stored at 20°C until nuclear magnetic resonance
(NMR) spectroscopy measurements were performed.10 This
method was used for trimethylamine-N-oxide (TMAO)
detection. Excretion in urine and in plasma was deter-
mined from the different spectra. TMAO is a metabolite
synthesized in the renal medulla from trimethylamine
precursor and an established marker for renal medulla
injury from different causes, which is a sensitive region of
the kidney for IRI.10 This metabolite fall sin the methyl-
amines category and is an organic osmolyte used in the
mammalian kidney for osmolytes system.20 For urine
spectra, the ratio of TMAO was calculated and expressed
in mmol per mol of creatinine. TMAO was also deter-
mined in plasma from spectra (TMAOp) and was noted
only when it was intense enough to be separated from
glucose resonances.
Western blotting. Pieces of snap-frozen kidney tis-
sues (cortex and outer medulla) collected at days 0 (before
WI), 1 (n 3), and 7 (n 3), and at month 3 (n 6) after
reperfusion were submitted to standard blotting protocols,
as described previously15 using the following antibodies:
hypoxia-inducible transcription factor-1 (HIF-1) (1:1000;
Novus Biologicals, Littleton, Colo) and Bax, Bcl-xL and caspase
3 (1:200; Santa Cruz Biotechnology, Santa Cruz, Calif). For
each immunoblot, -Actin (1:1000; Sigma-Aldrich, Saint
Quentin Fallavier, France) was used as the loading control.
Image-densitometric analysis of the immunoreactive protein
bands (one per animal) was performed and intensities of each
band were determined using densitometry and averaged in
each group. HIF-1was studied as a marker of tissue hypoxia,
Bax as a cell death accelerator, caspase 3 as an effector of
apoptosis, and Bcl-xL as a suppressor of apoptosis.21
Histopathological studies. After WI and reperfusion,
kidney tissue samples were collected from the deep cortex-
outer medulla region where the proximal tubule segments
are located which is particularly exposed to IRI in sacrificed
animals following an established protocol at days 1 and
7.2,9,10 Different histological criteria (tubular necrosis and
brush border injury) were quantified in 10 fields and ex-
pressed in percent of kidney samples using a previously
described semiquantitative scale by two pathologists
blinded to the experimental conditions:22 0 - no detection;
1 - criteria detected within less than 10% of kidney samples;
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3 - criteria detected within 25% to 50% of kidney samples;
4 - criteria detected within 50% to 75%; 5 - criteria detected
within more than 75% of kidney samples. Tubulointerstitial
injury was defined as inflammatory cell infiltrates, tubular
atrophy, or interstitial fibrosis. To estimate the level of
tubulointerstitial fibrosis, tissue sections were also labeled
with Picro Sirius for collagen identification (collagen I and
III) as recommended and following a standardized proce-
dure.23 Tubular atrophy was semiquantitatively scored on a
scale of 0 to 5 by two pathologists blinded to the experi-
Fig 1. Influence of trimetazidine on warm ischemia time on the
glomerular filtration rate (A), urinary protein excretion (B). The
values reported are the mean SE. *P 	 .05, **P 	 .01, ***P 	
.001 WI-60 and WI-60-TMZ1 mg groups vs WI-60-TMZ5 mg
and WI-60-TMZ10 mg groups and WI-60-TMZ5 mg and WI-
60-TMZ10 mg groups vs control and unif groups.
Table I. List of antibodies used for the histomorphologic
Reference Antibody
MCA1218 Mouse anti porcine
MCA1749 Mouse anti porcine

-SMA Mouse anti porcine
Vimentin Mouse anti porcinemental conditions as previously described.22Immunohistochemical studies. Frozen and paraffin-
embedded kidney sections (5 m) from biopsies were
processed for indirect immunohistochemistry using several
antibodies as previously described.22 All sections were ex-
amined under blind conditions and photographed. Anti-
bodies are presented in Table I. The number of MCA1218
and CD4 labeled cells per surface area (104/m2) was
counted on 8 to 12 different tissue sections for each of the
experimental conditions as described.9,10 The -SMA ex-
pression was determined (-SMA, 1:50; Sigma, Lyon,
France) and vimentin staining was used as mesenchymal
marker (1:100; Dakopatts, Glostrup, Denmark). In each
representative slide, -SMA and vimentin staining was
semiautomatically quantified in 15 fields using a computer-
aided image analysis method. The number of -SMA pos-
itive cells were counted and expressed as mean  SEM per
field of view (at 400 magnification, 15 counted fields).
The -SMA and vimentin expression are validated mesen-
chymal markers and their evaluation reflect the evolution of
epithelial to mesenchymal transition, which is defined as
the acquisition by epithelial cells of the phenotypic and
functional properties of mesenchymal fibroblast.
Statistical analysis. Quantitative parameters are pre-
sented as mean values SEM. Comparisons within groups
were performed using paired Student t test and among
groups using analysis of variance for multiple group com-
parisons, with the Bonferroni correction followed by un-
paired t test. When a nonparametric test was needed, the
Kruskall-Wallis one-way analysis of variance was used. One-
way analysis of variance (ANOVA) test was performed in
order to evaluate statistically significant changes in TMAO
excretion between the study groups. A P value 	.05 was
considered to be significant. Control and unif groups values
are shown in the figures as references.
RESULTS
Evolution of long-term renal functions and survival
after warm ischemia (WI) with and without trimeta-
zidine. The outcomes after warm ischemia and reperfu-
sion differed markedly between groups. Several animals
from nontreated groups died in postoperative days showing
the intensity of WI: 3 in WI-60 between days 9 and 12 and
3 in WI-60-TMZ1 mg between days 10 and 12. Survival
was 100% in control, unif, WI-60-TMZ5 mg, and WI-60-
TMZ10 mg, respectively. Renal functional data are shown
in Fig 1, A and B. During the first week, Ccr was reduced in
all experimental groups compared with control and unif
(Fig 1, A). Ccr recovery was significantly increased in the
dy
Specificity Origin
Monocytes/macrophages Serotec products
CD4 Serotec products

-smooth muscle actin Sigma
vimentin Dakopattsal stuTMZ-treated groups (5 and 10 mg/Kg, P 	 .05) versus
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 4 Cau et al 855WI-60 and WI-60-TMZ1 mg. However, Ccr from experi-
mental groups remained significantly different from control
and unif groups (P 	 .01) Progressive proteinuria devel-
oped after approximately 6 to 8 weeks. Higher levels of
proteinuria were detected in WI-60 and WI-60-TMZ1 mg
groups. When TMZ (5 and 10 mg/Kg) was administered
before WI, proteinuria was significantly reduced (Fig 1, B; P	
.01). TMZ reduced TMAO excretion in urine from pigs
that were treated with TMZ at a dose of 5 and 10 mg/Kg
(Fig 1, online only, C and D). This observation supports a
potential protective effect of TMZ on renal medulla after
IRI.
Evolution of cellular integrity of post reperfused
kidneys after warm ischemia times with and without
trimetazidine. Histological analysis of biopsy samples
from WI kidneys revealed no difference in the cellular
integrity after 24 hours of reperfusion (Table II). In turn, at
day 7 post reperfusion, the degree of residual acute proxi-
mal tubule cell injury appeared closely related to the TMZ
treatment, particularly after 5 and 10 mg/Kg perfusion
(Table II). WI-60 and WI-60-TMZ1 mg groups exhibited
Table II. Degree of proximal tubule cell after different tim
Injury types Time reperfusion WI-60 WI-6
Brush border injury
Day 1 2.1  0.2 2
Day 7 2.0  0.2 2
Tubular necrosis
Day 1 3.3  0.3 3
Day 7 2.7  0.2 2
The histological lesions from early (30 to 40 minutes), days 7 and 14 post war
border injury, tubular necrosis (characterized by swollen cells with granular c
 SD for all parameters analyzed.
*P 	 .05 WI-60-TMZ5 mg and 10 mg vs WI-60 and WI-60-TMZ1 mg.
Fig 2. Western blot analysis of HIF-1. HIF-1 express
at days 0, 1, and 7, and 3 months after reperfusion. A,
ischemia (see Material and Methods section) followed b
and uninephrectomized animals (unif) are compared
determined at days 0 (D0), 1 (D1), and 7 (D7), and 3 m
SD from three independent experiments. *P 	 .05 T
group, TMZ-treated (1 mg/Kg), **P 	 .01 TMZ-trea
TMZ-treated (1mg/Kg).a more intense residual proximal tubule injury with a sig-nificant loss of brush border. These data suggest that TMZ
treatment (5 and 10 mg/Kg) is protective against initial
renal injury. No abnormality was detected in the control
and unif groups (data not shown).
Effect of renal ischemia with and without trimeta-
zidine on HIF-1 protein expression in pig kidneys.
HIF-1 protein increased and peaked at day 7 after the
induction in ischemia and reperfusion in TMZ-treated
groups with 5 and 10 mg/kg compared with the non-TMZ-
treated and TMZ1 mg treated groups (Fig 2, A and B). In
turn, HIF-1 protein was delayed in no TMZ-treated and
TMZ1 mg treated groups (Fig 2, A and B). At 3 months,
HIF-1 is increased in WI-60 and WI-60-TMZ1 mg
groups compared with experimental groups treated with 5
and 10 mg groups. These data support that protection of
renal tissue is accompanied by a preserved HIF activity
resulting in improvement of renal function and tissue re-
generation when expressed in the early stage of reperfusion
and tissue regeneration. After 1 week and at the late stage of
reperfusion, the increased HIF expression in the TMZ-
untreated group, and the group treated with low dose of
warm ischemia
Z1 mg WI-60-TMZ5 mg WI-60-TMZ10 mg
0.3 2.0  0.2 2.0  0.3
0.3 1.3  0.2* 1.2  0.2*
0.2 3.0  0.2 3.1  0.2
0.2 2.2  0.2* 2.2  0.2*
emia were evaluated and given as a semiquantitative score (Methods). Brush
sm and mitotic figures) were examined in light microscopy. Values are means
as examined by western blot in cortex and outer medulla
esentative immunoblots for HIF-1 after experimental
erfusion. HIF-1 expression in normal kidney (control)
r experimental conditions. B, Expression of HIF-1
s (M3) after reperfusion. Data were presented as means
treated (5 and 10 mg/Kg) groups vs TMZ-untreated
5 and 10 mg/Kg) groups vs non-TMZ-treated group,e of
0-TM
.2 
.1 
.4 
.8 
m isch
ytoplaion w
repr
y rep
unde
onth
MZ-
ted (TMZ (1 mg/Kg) seemed to parallel the development of
d WI
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HIF expression during the period of reperfusion.
Effect of renal ischemia with and without trimeta-
zidine on apoptosis in pig kidneys. The expression of
caspase 3 was reduced at days 1 and 7 in TMZ-treated
groups by 5 and 10 mg/Kg (Fig 3, A and B). At 3 months,
the expression of caspase 3 was similar among the different
groups (Fig 3, C). In turn, Bax expression was increased
and Bcl-xL was decreased in the non-TMZ-treated group
and TMZ-treated group by 1 mg/Kg (Fig 3, A and B). At
3 months, the expression of Bax and Bcl-xL was similar
among the different groups (Fig 3, C). These data sug-
gested that TMZ effect may be related to an effect on
apoptosis through caspase-dependent pathway during the
first week after reperfusion.
Effect of warm ischemia on cellular infiltration in
pig kidneys with and without trimetazidine. In accor-
dance with previous studies, the major inflammatory cell
population detected by immunohistochemical studies was
CD4 T lymphocytes. No infiltrating cell was detected in
Fig 3. Renal protein densitometry and representative im
(middle), and month 3 (bottom). *P 	 .05 vs normal ancontrol and unif groups (data not shown). In contrast, thenumber of CD4 increased after WI, particularly WI-60
and WI-60-TMZ1 mg (Fig 4, online only, A). In WI-60
and WI-60-TMZ1 mg groups, monocyte/macrophage in-
creased between W1 to W2, plateaued between W2 and
W6, and slightly decreased between W6 and W12 (Fig 4,
online only, B). TMZ treatment reduced the inflammatory
response in experimental groups treated with 5 and 10
mg/Kg.
Effect of warm ischemia on the onset of interstitial
fibrosis with and without trimetazidine. Evolution of
interstitial fibrosis is presented in Fig 5, upper panel and Fig
5, A to 5, D (lower panel). In our hands, fibrosis is corre-
lated with WI, particularly after 60 minutes and TMZ
treatment at 1 mg/Kg (Fig 5, A and B). Within kidneys
from TMZ-treated groups (5 or 10 mg/Kg), fibrosis de-
velopment was reduced (Fig 5, C and D). Staining for
-SMA and vimentin was marked in WI-60 and WI-60-
TMZ1 mg (Fig 6, upper and middle panel; P 	 .05).
Positive cells for -SMA were significantly increased in
WI-60 and WI-60-TMZ1 mg (P	 .01). Collectively, these
oblots of the regulator of apoptosis at day 1 (top), day 7
-60 or WI-60-TMZ1 mg.mundata support a protective role of TMZ in a renal model of
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markers involved in renal recovery
DISCUSSION
In the present report, TMZ treatment is protective
against renal IRI at a dose of 5 and 10 mg/Kg in an in vivo
pig model of renal WI. This dose effect study brings infor-
mation on the more efficient dose, which is 5 mg/kg. The
dose of 10 mg/kg did not increase TMZ efficiency suggest-
ing a mechanism of action, which could be saturated. This
supports the role of specific binding sites for TMZ and a
physiological relevance as previously suggested.24 This was
clearly observed particularly for tubular injury at day 7
compared with the one observed after 24 hours of reperfu-
sion. In addition, this dose of 5 mg/kg of TMZ was
recently suggested to inhibit mPTP and prevent lethal IR
injury after coronary artery occlusion.16 These data suggest
that TMZ could limit tissue injury and organ dysfunction
after WI. Limitation of cortex and medulla injury was also
supported by TMAO release which was reduced in TMZ-
treated groups with 5 and 10 mg/Kg. Because this osmolyte
is synthesized in the renal medulla and is an established marker
of medullary renal injury and loss of integrity, this supports the
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Fig 5. Influence of warm ischemia on the onset of tubu
interstitial fibrosis stained with Picrosirius was measured
between W8 and W12 (upper panel). Middle panel: Tubu
at W12 is shown in lower panel (A, WI-60, B, WI-60-TM
Lower panel: tubular atrophy was determined following
values reported are the mean  SD. *P 	 .05, **P 	
WI-60-TMZ10 mg.protective effect of TMZ on renal medulla.10,25The role of apoptosis and more precisely, the role of
mPTP has been highlighted in different experimental con-
ditions such as renal hypoxia and ischemia.7,26 In hypoxic
renal cells, Bax and Bak, 2 pro-apoptotic proteins of the
Bcl-2 family, collaborate to permeabilize the mitochondrial
outer membrane to intermembrane proteins such as cyto-
chrome c (Cyt c), although Bax, per se, appears to play the
dominant role. Cyt c then acts to trigger the downstream
apoptotic cascade. However, the anti-apoptotic Bcl-2 pre-
vents mitochondrial permeabilization and maintains viabil-
ity. Recently, Yin et al have established that TMZ could
limit apoptotic death in cultured astrocytes submitted to
hypoxia-reoxygenation.27 Recent studies has confirmed
that the low-affinity TMZ sites on mitochondria are in-
volved in the inhibition of mitochondrial swelling and this
behavior was associated to an inhibition of mitochondrial
transition pore opening.28 In the present study, TMZ effect
could be correlated to the down regulation of Bcl-xL
during the early stage of reperfusion after WI.
An important aspect of the renal adaptation is oxygen-
ated-dependent gene regulation mediated by the hypoxia-
inducible transcription factors (HIF). Induction of HIF-1
is an early event in the sequence of cellular changes follow-
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kidney.29-32 In normoxic conditions (day 0, unif and con-
trol), HIF-1 was not detectable. In the TMZ-treated
animals with either 5 or 10 mg/Kg, HIF-1 is detected at
day 1 and peaked at day 7. In turn, HIF-1 expression is
delayed in no TMZ-treated group and WI-60-TMZ1 mg
treated group. This delayed expression of HIF-1 in low
dose TMZ-treated and non-TMZ-treated groups suggest a
limitation of adaptive response.29-30 The delayed expres-
sion of HIF-1 could be also related to renal damage level
in these groups and an HIF-1-related adaptative cell
response, which has diminished or disappeared. Although
the underlying mechanism remains to be clarified, these
data suggest a potential role between HIF-1 and the
differentiation and transition of renal epithelial to mesen-
chymal fibroblast-like cells as previously suggested in other
different biological systems (for a review see Haase32). In
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.05, **P 	 .01 WI-60 or WI-60-TMZ1 mg vs WI-60-Tthe present study, this hypothesis was supported by thevimentin expression, a marker of epithelial to mesenchymal
transition and correlated to loss of epithelial features.33 In
addition, at 3 months, staining of with -SMA was also
reduced in WI-TMZ5 mg and WI-TMZ10 mg suggesting
a limitation of fibroblasts in the interstitium. The -SMA
positive cells were also reduced in this model by TMZ
treatment, and these data have to be analyzed with intersti-
tial fibrosis development. However, we are not able to
make any difference in the origin of these cells between
vascular smooth muscle cells, pericytes, or myofibroblast,
but we have noted that -SMA positive cells were found
particularly in perivascular regions suggesting that shed-
ding of vascular of smooth muscle cells and pericytes con-
tributes to the population of -SMA positive cells in the
fibrotic interstitium. A recent report has also described the
role of HIF-1 as a mediator of progenitor cell recruitment
to injured tissue.34 In our study, the correlation between
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report. As a consequence, renal protection with drug as
TMZ could be explained by this mechanism during the first
week after reperfusion suggesting that HIF-1 is an impor-
tant mediator during the renal repair process.
The other important finding is the impact of adminis-
tration of TMZ (constant infusion for 24 hours) before WI
on IRI and inflammation processes. Studies have shown
that early IRI can lead to the initiation of inflammatory
cascade.35,36 Inflammation is a significant component of
renal IRI playing a considerable role in its pathophysiology.
Recent studies suggest that the apoptosis-related mecha-
nisms contribute to the inflammatory process (for a review,
see Saikumar and Venkatachalam17). Polymorphonuclear
cells recruited during reperfusion have long been impli-
cated as critical mediators of the renal parenchymal injury in
ischemic ARF.2 These polymorphonuclear cells may con-
tribute by potentiating an inflammatory response that leads
to the generation of vasoconstrictor agents, cytokines, and
toxic mediators such as ROS and proteases.37 Recently, it
has been demonstrated that after severe warm IR renal
injury, significant monocytes/macrophages infiltration oc-
curred at the outer stripe of outer medulla at 24 hours after
post-ischemia became prominent at day 5 and almost dis-
appeared after 10 days. Evidence from different laborato-
ries now supports a role for T cells as modulators of renal
IRI, particularly in rodent models (for a review, see Burne-
Taney and Rabb 37). ROS generated during IRI, can also
activate T cells.38-40 The limitation of WI deleterious ef-
fects by TMZ is correlated with the limitation of damage
after 60 minutes of WI. This modulation involved inflam-
mation within kidney tissues and particularly CD4 cells
infiltration. This effect could be related to an effect of TMZ
on endothelial cells and more particularly to an antioxidant
effect as suggested in an in vivo study.41,42 In addition, our
data bring support to previous studies on the role of CD4
T cell as a major pathogenic factor in ischemic acute renal
failure and the implication for renal protection.
An additional mechanism that may lead to TMZ pro-
tection is the effect on apoptosis. We observed that TMZ
modulates the expression of proapoptotic and antiapop-
totic proteins. Because the relative proportion of pro- and
antiapoptotic proteins in an important factor in determin-
ing cellular death and survival, this could explain the role of
TMZ in renal recovery and tissue repair process. Our data
report that TMZ treatment is associated with a down
regulation of Bcl-xL, a suppressor of apoptosis.17 In turn,
Bax (a cell death accelerator) and caspase 3 (an important
effector of apoptosis) expression are increased in the non-
TMZ-treated and low dose TMZ groups.
In summary, we observed that TMZ at doses of 5 and
10 mg has renal protective effects in the setting of IRI. This
drug, which targets mitochondrial metabolism as sug-
gested in different models, could be useful in case of major
aortic reconstruction necessitating a supra renal cross
clamping, like for thoracoabdominal or supra renal aneu-
rysm and renal artery revascularization procedures. The last
but not the least point is that TMZ treatment at the earlystage of renal IRI could have some beneficial indirect
interest to limit long-term deleterious consequences of
renal IRI.
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Materials and Methods
Functional parameters. As previously described,
urine and plasma samples from animals in control, unif, and
ischemic kidney groups were collected and stored at20°C
until NMR spectroscopy measurements were performed.10
This method was used for TMAO detection. Excretion in
urine and plasma was determined from the different spec-
tra. TMAO is a metabolite synthesized in the renal medulla
from trimethylamine precursor and an established marker
for renal medulla injury from different causes, which is a
sensitive region of the kidney for IRI.10 This metabolite
falls in the methylamines category and is an organic os-
molyte used in the mammalian kidney for osmolytes sys-
tem.20 For urine spectra, the ratio of trimethylamine-N-
oxide (TMAO) was calculated and expressed in mmol per
mol of creatinine. TMAO was also determined in plasma
from spectra (TMAOp) and was noted only when it was
intense enough to be separated from glucose resonances.
Western blotting. For details, see online supplement.
Pieces of snap-frozen kidney tissues (cortex and outer me-
dulla) collected at days 0 (before WI), 1 (n 3), 7 (n 3),
and at month 3 (n  6) after reperfusion was submitted to
standard blotting protocols, as described previously15 using
the following antibodies: HIF-1 (1:1000; Novus Biologi-
cals, Littleton, Colo) and Bax, Bcl-xL, and caspase 3 (1:
200; Santa Cruz Biotechnology, Santa Cruz, Calif). For
each immunoblot, -Actin (1:1000; Sigma) was used as the
loading control. Image-densitometric analysis of the im-
munoreactive protein bands (one per animal) was per-
formed, and intensities of each band were determined using
densitometry and averaged in each group. HIF-1 was
studied as a marker of tissue hypoxia, Bax as a cell death
ularly in rodent models (for a review, see Burne-Taney andaccelerator, caspase 3 as an effector of apoptosis, and Bcl-xL
as a suppressor of apoptosis.21
Immunohistochemical studies. All sections were ex-
amined under blind conditions and photographed. Anti-
bodies are presented in Table I. The number of MCA1218
and CD4 labeled cells per surface area (104/m2) was
counted on 8 to 12 different tissue sections for each of the
experimental conditions as described.9,10
Results
Evolution of TMAO excretion in urine and plasma
after warm ischemia with and without trimetazidine.
TMZ reduced TMAO excretion in urine from pigs that
were treated with TMZ at a dose of 5 and 10 mg/Kg (Fig
1, online only, C and D). This observation supports a
potential protective effect of TMZ on renal medulla after
IRI.
Effect of warm ischemia on cellular infiltration in
pig kidneys with and without trimetazidine. In accor-
dance with previous studies, the major inflammatory cell
population detected by immunohistochemical studies was
CD4 T lymphocytes. No infiltrating cell was detected in
control and unif groups (data not shown). In contrast, the
number of CD4 increased after WI, particularly WI-60
and WI-60-TMZ1 mg (Fig 4, online only, A). In WI-60
and WI-60-TMZ1mg groups, monocyte/macrophage in-
creased between W1 to W2, plateaued between W2 and
W6, and slightly decreased between W6 and W12 (Fig 4,
online only, B). TMZ treatment reduced the inflammatory
response in experimental groups treated with 5 and 10
mg/Kg.DISCUSSION
Limitation of cortex and medulla injury was also supported by
TMAO release, which was reduced in the TMZ-treated groups by
5 and 10 mg/Kg. Because this osmolyte is synthesized in the renal
medulla and is an established marker of medullary renal injury and
loss of integrity, this supports the protective effect of TMZ on renal
medulla.10,25 The other important finding is the impact of admin-
istration of TMZ (constant infusion for 24 hours) before WI on
IRI and inflammation processes. Studies have shown that early IRI
can lead to the initiation of inflammatory cascade.35,36 Inflamma-
tion is a significant component of renal IRI playing a considerable
role in its pathophysiology. Recent studies suggest that the apop-
tosis-related mechanisms contribute to the inflammatory process
(for a review, see Saikumar and Venkatachalam17). Polymorpho-
nuclear cells recruited during reperfusion have long been impli-
cated as critical mediators of the renal parenchymal injury in
ischemic ARF.2 These polymorphonuclear cells may contribute by
potentiating an inflammatory response that leads to the generation
of vasoconstrictor agents, cytokines, and toxic mediators such as
ROS and proteases.37 Recently, it has been demonstrated that after
severe warm IR renal injury, significant monocytes/macrophages
infiltration occurred at the outer stripe of outer medulla at 24
hours after post-ischemia, became prominent at day 5 and almost
disappeared after 10 days. Evidence from different laboratories
now supports a role for T cells as modulators of renal IRI, partic-Rabb37). ROS generated during IRI, can also activate T cells.38-40
The limitation of WI deleterious effects by TMZ is correlated with
the limitation of damage after 60 minutes of WI. This modulation
involved inflammation within kidney tissues and particularly CD4
cells infiltration. This could be related to an effect of TMZ on
endothelial cells and more particularly to an antioxidant effect as
suggested in an in vivo study.39,40 In addition, our data support
previous studies on the role of CD4 T cell as a major pathogenic
factor in ischemic acute renal failure and the implication for renal
protection.
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Fig 4, online only. Effect of warm ischemia time inflammation in post reperfused kidney. A, CD4 cells, and B,
monocyte/macrophages. The number of positively stained per surface area were counted on biopsy samples from
experimental groups. The values reported are the mean SE from 8 to 12 separate determinations. The values reported
are the meanSE. *P	 .05, **P	 .01 WI-60 and WI-60-TMZ1 mg, vs WI-60-TMZ5 mg and WI-60-TMZ10 mg.
